#METABOLOMICS WORKBENCH kmwiese_20181115_075135 DATATRACK_ID:1570 STUDY_ID:ST001098 ANALYSIS_ID:AN001786 PROJECT_ID:PR000734
VERSION             	1
CREATED_ON             	November 25, 2018, 11:32 am
#PROJECT
PR:PROJECT_TITLE                 	Metabolomics of Metabolic Risk in Patients Taking Atypical Antipsychotics
PR:PROJECT_TYPE                  	NMR and GC fatty acid analysis
PR:PROJECT_SUMMARY               	STUDY OBJECTIVE Patients with schizophrenia are known to have higher rates of
PR:PROJECT_SUMMARY               	metabolic disease than the general population. Contributing factors likely
PR:PROJECT_SUMMARY               	include lifestyle and atypical antipsychotic (AAP) use, but the underlying
PR:PROJECT_SUMMARY               	mechanisms are unknown. The objective of this study was to identify metabolomics
PR:PROJECT_SUMMARY               	variability in adult patients with schizophrenia who were taking AAPs and
PR:PROJECT_SUMMARY               	grouped by fasting insulin concentration, our surrogate marker for metabolic
PR:PROJECT_SUMMARY               	risk. DESIGN Metabolomics analysis. PARTICIPANTS Ninety-four adult patients with
PR:PROJECT_SUMMARY               	schizophrenia who were taking an AAP for at least 6 months, with no changes in
PR:PROJECT_SUMMARY               	their antipsychotic regimen for the previous 8 weeks, and who did not require
PR:PROJECT_SUMMARY               	treatment with insulin. Twenty age- and sex-matched nonobese (10 subjects) and
PR:PROJECT_SUMMARY               	obese (10 subjects) controls without cardiovascular disease or mental health
PR:PROJECT_SUMMARY               	diagnoses were used to match the body mass index range of the patients with
PR:PROJECT_SUMMARY               	schizophrenia to account for metabolite concentration differences attributable
PR:PROJECT_SUMMARY               	to body mass index. MEASUREMENTS AND MAIN RESULTS Existing serum samples were
PR:PROJECT_SUMMARY               	used to identify aqueous metabolites (to differentiate fasting insulin
PR:PROJECT_SUMMARY               	concentration quartiles) and fatty acids with quantitative nuclear magnetic
PR:PROJECT_SUMMARY               	resonance (NMR) and gas chromatography (GC) methods, respectively. To exclude
PR:PROJECT_SUMMARY               	metabolites from our pathway mapping analysis that were due to variability in
PR:PROJECT_SUMMARY               	weight, we also subjected serum samples from the nonobese and obese controls to
PR:PROJECT_SUMMARY               	the same analyses. Patients with schizophrenia had a median age of 47.0
PR:PROJECT_SUMMARY               	(interquartile range 41.0-52.0) years. Using a false discovery rate threshold of
PR:PROJECT_SUMMARY               	<25%, 10 metabolites, not attributable to weight, differentiated insulin
PR:PROJECT_SUMMARY               	concentration quartiles in patients with schizophrenia and identified
PR:PROJECT_SUMMARY               	variability in one-carbon metabolism between groups. Patients with higher
PR:PROJECT_SUMMARY               	fasting insulin concentrations (quartiles 3 and 4) also trended toward having
PR:PROJECT_SUMMARY               	higher levels of saturated fatty acids compared with patients with lower fasting
PR:PROJECT_SUMMARY               	insulin concentrations (quartiles 1 and 2). CONCLUSION These results illustrate
PR:PROJECT_SUMMARY               	the utility of metabolomics to identify pathways underlying variable fasting
PR:PROJECT_SUMMARY               	insulin concentration in patients with schizophrenia. Importantly, no
PR:PROJECT_SUMMARY               	significant difference in AAP exposure was observed among groups, suggesting
PR:PROJECT_SUMMARY               	that current antipsychotic use may not be a primary factor that differentiates
PR:PROJECT_SUMMARY               	middle-aged adult patients with schizophrenia by fasting insulin concentration.
PR:PROJECT_SUMMARY               	This article is protected by copyright. All rights reserved. As published in
PR:PROJECT_SUMMARY               	Pharmacotherapy. 2018 Jun;38(6):638-650.
PR:INSTITUTE                     	University of Michigan
PR:LAST_NAME                     	Stringer
PR:FIRST_NAME                    	Kathleen
PR:ADDRESS                       	428 Church St
PR:EMAIL                         	stringek@umich.edu
PR:PHONE                         	734-647-4775
PR:FUNDING_SOURCE                	Funding for this work was supported in part by grants from the following
PR:FUNDING_SOURCE                	centers: the University of Michigan Claude D. Pepper Older Americans
PR:FUNDING_SOURCE                	Independence Center (National Institute on Aging [NIA] grantAGA024824); the
PR:FUNDING_SOURCE                	University of Michigan’s Nutrition Obesity Research Center (grant DK089503)
PR:FUNDING_SOURCE                	and Weight Management Program, and the Michigan Regional Comprehensive
PR:FUNDING_SOURCE                	Metabolomics Resource Core (grant DK097153),the Michigan Center for Diabetes
PR:FUNDING_SOURCE                	Translational Research(grant P30DK092926), and the A. Alfred Taubman Medical
PR:FUNDING_SOURCE                	Institute and the Robert C. and Veronica Atkins Foundation. This work was also
PR:FUNDING_SOURCE                	supported in part by a metabolomics supplement to a grant from the National
PR:FUNDING_SOURCE                	Institute of Mental Health (NIMH; grant MH082784; Dr. Ellingrod). Dr.
PR:FUNDING_SOURCE                	Stringer’s effort is supported in part by a grant from the National Institute
PR:FUNDING_SOURCE                	of General Medical Sciences (NIGMS; grant GM111400). Dr. Rothberg’s effort is
PR:FUNDING_SOURCE                	supported in part by DK089503.
PR:PUBLICATIONS                  	Pharmacotherapy. 2018 Jun;38(6):638-650
#STUDY
ST:STUDY_TITLE                   	Metabolomics of Metabolic Risk in Patients Taking Atypical Antipsychotics (part
ST:STUDY_TITLE                   	II)
ST:STUDY_SUMMARY                 	STUDY OBJECTIVE Patients with schizophrenia are known to have higher rates of
ST:STUDY_SUMMARY                 	metabolic disease than the general population. Contributing factors likely
ST:STUDY_SUMMARY                 	include lifestyle and atypical antipsychotic (AAP) use, but the underlying
ST:STUDY_SUMMARY                 	mechanisms are unknown. The objective of this study was to identify metabolomics
ST:STUDY_SUMMARY                 	variability in adult patients with schizophrenia who were taking AAPs and
ST:STUDY_SUMMARY                 	grouped by fasting insulin concentration, our surrogate marker for metabolic
ST:STUDY_SUMMARY                 	risk. DESIGN Metabolomics analysis. PARTICIPANTS Ninety-four adult patients with
ST:STUDY_SUMMARY                 	schizophrenia who were taking an AAP for at least 6 months, with no changes in
ST:STUDY_SUMMARY                 	their antipsychotic regimen for the previous 8 weeks, and who did not require
ST:STUDY_SUMMARY                 	treatment with insulin. Twenty age- and sex-matched nonobese (10 subjects) and
ST:STUDY_SUMMARY                 	obese (10 subjects) controls without cardiovascular disease or mental health
ST:STUDY_SUMMARY                 	diagnoses were used to match the body mass index range of the patients with
ST:STUDY_SUMMARY                 	schizophrenia to account for metabolite concentration differences attributable
ST:STUDY_SUMMARY                 	to body mass index. MEASUREMENTS AND MAIN RESULTS Existing serum samples were
ST:STUDY_SUMMARY                 	used to identify aqueous metabolites (to differentiate fasting insulin
ST:STUDY_SUMMARY                 	concentration quartiles) and fatty acids with quantitative nuclear magnetic
ST:STUDY_SUMMARY                 	resonance (NMR) and gas chromatography (GC) methods, respectively. To exclude
ST:STUDY_SUMMARY                 	metabolites from our pathway mapping analysis that were due to variability in
ST:STUDY_SUMMARY                 	weight, we also subjected serum samples from the nonobese and obese controls to
ST:STUDY_SUMMARY                 	the same analyses. Patients with schizophrenia had a median age of 47.0
ST:STUDY_SUMMARY                 	(interquartile range 41.0-52.0) years. Using a false discovery rate threshold of
ST:STUDY_SUMMARY                 	<25%, 10 metabolites, not attributable to weight, differentiated insulin
ST:STUDY_SUMMARY                 	concentration quartiles in patients with schizophrenia and identified
ST:STUDY_SUMMARY                 	variability in one-carbon metabolism between groups. Patients with higher
ST:STUDY_SUMMARY                 	fasting insulin concentrations (quartiles 3 and 4) also trended toward having
ST:STUDY_SUMMARY                 	higher levels of saturated fatty acids compared with patients with lower fasting
ST:STUDY_SUMMARY                 	insulin concentrations (quartiles 1 and 2). CONCLUSION These results illustrate
ST:STUDY_SUMMARY                 	the utility of metabolomics to identify pathways underlying variable fasting
ST:STUDY_SUMMARY                 	insulin concentration in patients with schizophrenia. Importantly, no
ST:STUDY_SUMMARY                 	significant difference in AAP exposure was observed among groups, suggesting
ST:STUDY_SUMMARY                 	that current antipsychotic use may not be a primary factor that differentiates
ST:STUDY_SUMMARY                 	middle-aged adult patients with schizophrenia by fasting insulin concentration.
ST:STUDY_SUMMARY                 	This article is protected by copyright. All rights reserved. As published in
ST:STUDY_SUMMARY                 	Pharmacotherapy. 2018 Jun;38(6):638-650.
ST:INSTITUTE                     	University of Michigan
ST:LAST_NAME                     	Stringer
ST:FIRST_NAME                    	Kathleen
ST:ADDRESS                       	428 Church St
ST:EMAIL                         	kmwiese@umich.edu
ST:PHONE                         	7346474775
#SUBJECT
SU:SUBJECT_TYPE                  	Human
SU:SUBJECT_SPECIES               	Homo sapiens
SU:TAXONOMY_ID                   	9606
SU:AGE_OR_AGE_RANGE              	30-60 years old
SU:WEIGHT_OR_WEIGHT_RANGE        	52.3-176.6 kg
SU:GENDER                        	Male and female
SU:HUMAN_MEDICATIONS             	To be included in the study all participants had to be taking an atypical
SU:HUMAN_MEDICATIONS             	(second-generation) antipsychotic
SU:HUMAN_INCLUSION_CRITERIA      	DSM IV diagnosis of a schizophrenia spectrum diagnosis who had been taking an
SU:HUMAN_INCLUSION_CRITERIA      	atypical antipsychotic for at least 6 months, with no changes in antipsychotic
SU:HUMAN_INCLUSION_CRITERIA      	regimen for 8 weeks preceding the baseline visit. Twenty age and sex matched
SU:HUMAN_INCLUSION_CRITERIA      	obese and nonobese participants without mental health diagnoses were included to
SU:HUMAN_INCLUSION_CRITERIA      	match the BMI range of the patients with schizophrenia as BMI controls.
SU:HUMAN_EXCLUSION_CRITERIA      	Current use of insulin, diagnosis of diabetes mellitus type 2 prior to
SU:HUMAN_EXCLUSION_CRITERIA      	antipsychotic exposure, active substance abuse diagnosis
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data
SUBJECT_SAMPLE_FACTORS           	-	Q005	Treatment:Obese control	BMI=35.9; Fasting Insulin (mU/mL) =19.1
SUBJECT_SAMPLE_FACTORS           	-	Q025	Treatment:Obese control	BMI=32.0; Fasting Insulin (mU/mL) =11.0
SUBJECT_SAMPLE_FACTORS           	-	Q077	Treatment:Obese control	BMI=34.6; Fasting Insulin (mU/mL) =13.0
SUBJECT_SAMPLE_FACTORS           	-	Q160	Treatment:Obese control	BMI=34.7; Fasting Insulin (mU/mL) =17.5
SUBJECT_SAMPLE_FACTORS           	-	Q308	Treatment:Obese control	BMI=36.9; Fasting Insulin (mU/mL) =27.4
SUBJECT_SAMPLE_FACTORS           	-	Q442	Treatment:Obese control	BMI=36.8; Fasting Insulin (mU/mL) =40.1
SUBJECT_SAMPLE_FACTORS           	-	Q504	Treatment:Obese control	BMI=33.4; Fasting Insulin (mU/mL) =10.4
SUBJECT_SAMPLE_FACTORS           	-	Q610	Treatment:Obese control	BMI=33.2; Fasting Insulin (mU/mL) =11.9
SUBJECT_SAMPLE_FACTORS           	-	Q632	Treatment:Obese control	BMI=36.7; Fasting Insulin (mU/mL) =13.4
SUBJECT_SAMPLE_FACTORS           	-	Q897	Treatment:Obese control	BMI=33.7; Fasting Insulin (mU/mL) =12.0
SUBJECT_SAMPLE_FACTORS           	-	CCMB_04	Treatment:Non-obese control	BMI=25.9; Fasting Insulin (mU/mL) =14.8
SUBJECT_SAMPLE_FACTORS           	-	CCMB_05	Treatment:Non-obese control	BMI=27.8; Fasting Insulin (mU/mL) =11.1
SUBJECT_SAMPLE_FACTORS           	-	CCMB_15	Treatment:Non-obese control	BMI=25.2; Fasting Insulin (mU/mL) =14.7
SUBJECT_SAMPLE_FACTORS           	-	CCMB_17	Treatment:Non-obese control	BMI=25.5; Fasting Insulin (mU/mL) =14.6
SUBJECT_SAMPLE_FACTORS           	-	CCMB_19	Treatment:Non-obese control	BMI=21.0; Fasting Insulin (mU/mL) =10.7
SUBJECT_SAMPLE_FACTORS           	-	P2721_22	Treatment:Non-obese control	BMI=21.0; Fasting Insulin (mU/mL) =11.0
SUBJECT_SAMPLE_FACTORS           	-	P2721_23	Treatment:Non-obese control	BMI=20.7; Fasting Insulin (mU/mL) =13.0
SUBJECT_SAMPLE_FACTORS           	-	P2721_27	Treatment:Non-obese control	BMI=26.7; Fasting Insulin (mU/mL) =14.1
SUBJECT_SAMPLE_FACTORS           	-	P2721_28	Treatment:Non-obese control	BMI=29.4; Fasting Insulin (mU/mL) =15.3
SUBJECT_SAMPLE_FACTORS           	-	P2721_40	Treatment:Non-obese control	BMI=20.0; Fasting Insulin (mU/mL) =11.3
SUBJECT_SAMPLE_FACTORS           	-	V001	Treatment:Schizophrenia dx	BMI=31.0; Fasting Insulin (mU/mL) =13.7
SUBJECT_SAMPLE_FACTORS           	-	V003	Treatment:Schizophrenia dx	BMI=28.3; Fasting Insulin (mU/mL) =27.7
SUBJECT_SAMPLE_FACTORS           	-	V004	Treatment:Schizophrenia dx	BMI=30.7; Fasting Insulin (mU/mL) =15.7
SUBJECT_SAMPLE_FACTORS           	-	V008	Treatment:Schizophrenia dx	BMI=30.0; Fasting Insulin (mU/mL) =22.2
SUBJECT_SAMPLE_FACTORS           	-	V009	Treatment:Schizophrenia dx	BMI=29.5; Fasting Insulin (mU/mL) =9.5
SUBJECT_SAMPLE_FACTORS           	-	V011	Treatment:Schizophrenia dx	BMI=21.8; Fasting Insulin (mU/mL) =13.4
SUBJECT_SAMPLE_FACTORS           	-	V012	Treatment:Schizophrenia dx	BMI=38.3; Fasting Insulin (mU/mL) =21.6
SUBJECT_SAMPLE_FACTORS           	-	V013	Treatment:Schizophrenia dx	BMI=28.0; Fasting Insulin (mU/mL) =28.1
SUBJECT_SAMPLE_FACTORS           	-	V014	Treatment:Schizophrenia dx	BMI=43.3; Fasting Insulin (mU/mL) =31.1
SUBJECT_SAMPLE_FACTORS           	-	V015	Treatment:Schizophrenia dx	BMI=24.0; Fasting Insulin (mU/mL) =14.3
SUBJECT_SAMPLE_FACTORS           	-	V018	Treatment:Schizophrenia dx	BMI=25.6; Fasting Insulin (mU/mL) =7.9
SUBJECT_SAMPLE_FACTORS           	-	V019	Treatment:Schizophrenia dx	BMI=30.3; Fasting Insulin (mU/mL) =10.1
SUBJECT_SAMPLE_FACTORS           	-	V023	Treatment:Schizophrenia dx	BMI=23.2; Fasting Insulin (mU/mL) =10.0
SUBJECT_SAMPLE_FACTORS           	-	V029	Treatment:Schizophrenia dx	BMI=33.9; Fasting Insulin (mU/mL) =20.7
SUBJECT_SAMPLE_FACTORS           	-	V032	Treatment:Schizophrenia dx	BMI=40.1; Fasting Insulin (mU/mL) =47.4
SUBJECT_SAMPLE_FACTORS           	-	V033	Treatment:Schizophrenia dx	BMI=38.7; Fasting Insulin (mU/mL) =20.6
SUBJECT_SAMPLE_FACTORS           	-	V034	Treatment:Schizophrenia dx	BMI=35.9; Fasting Insulin (mU/mL) =31.3
SUBJECT_SAMPLE_FACTORS           	-	V035	Treatment:Schizophrenia dx	BMI=28.2; Fasting Insulin (mU/mL) =18.7
SUBJECT_SAMPLE_FACTORS           	-	V037	Treatment:Schizophrenia dx	BMI=24.9; Fasting Insulin (mU/mL) =23.9
SUBJECT_SAMPLE_FACTORS           	-	V041	Treatment:Schizophrenia dx	BMI=28.7; Fasting Insulin (mU/mL) =10.6
SUBJECT_SAMPLE_FACTORS           	-	V045	Treatment:Schizophrenia dx	BMI=30.1; Fasting Insulin (mU/mL) =9.0
SUBJECT_SAMPLE_FACTORS           	-	V046	Treatment:Schizophrenia dx	BMI=37.1; Fasting Insulin (mU/mL) =19.3
SUBJECT_SAMPLE_FACTORS           	-	V047	Treatment:Schizophrenia dx	BMI=26.3; Fasting Insulin (mU/mL) =15.3
SUBJECT_SAMPLE_FACTORS           	-	V048	Treatment:Schizophrenia dx	BMI=44.3; Fasting Insulin (mU/mL) =23.4
SUBJECT_SAMPLE_FACTORS           	-	V049	Treatment:Schizophrenia dx	BMI=26.4; Fasting Insulin (mU/mL) =14.7
SUBJECT_SAMPLE_FACTORS           	-	V052	Treatment:Schizophrenia dx	BMI=32.8; Fasting Insulin (mU/mL) =26.1
SUBJECT_SAMPLE_FACTORS           	-	V055	Treatment:Schizophrenia dx	BMI=36.9; Fasting Insulin (mU/mL) =20.2
SUBJECT_SAMPLE_FACTORS           	-	V056	Treatment:Schizophrenia dx	BMI=27.7; Fasting Insulin (mU/mL) =21.9
SUBJECT_SAMPLE_FACTORS           	-	V057	Treatment:Schizophrenia dx	BMI=51.5; Fasting Insulin (mU/mL) =99.0
SUBJECT_SAMPLE_FACTORS           	-	V063	Treatment:Schizophrenia dx	BMI=31.8; Fasting Insulin (mU/mL) =16.1
SUBJECT_SAMPLE_FACTORS           	-	V066	Treatment:Schizophrenia dx	BMI=44.7; Fasting Insulin (mU/mL) =16.0
SUBJECT_SAMPLE_FACTORS           	-	V068	Treatment:Schizophrenia dx	BMI=27.7; Fasting Insulin (mU/mL) =7.7
SUBJECT_SAMPLE_FACTORS           	-	V071	Treatment:Schizophrenia dx	BMI=28.8; Fasting Insulin (mU/mL) =13.6
SUBJECT_SAMPLE_FACTORS           	-	V079	Treatment:Schizophrenia dx	BMI=30.4; Fasting Insulin (mU/mL) =11.3
SUBJECT_SAMPLE_FACTORS           	-	V084	Treatment:Schizophrenia dx	BMI=39.5; Fasting Insulin (mU/mL) =60.5
SUBJECT_SAMPLE_FACTORS           	-	V087	Treatment:Schizophrenia dx	BMI=28.2; Fasting Insulin (mU/mL) =25.5
SUBJECT_SAMPLE_FACTORS           	-	V089	Treatment:Schizophrenia dx	BMI=23.9; Fasting Insulin (mU/mL) =9.1
SUBJECT_SAMPLE_FACTORS           	-	V092	Treatment:Schizophrenia dx	BMI=38.7; Fasting Insulin (mU/mL) =26.5
SUBJECT_SAMPLE_FACTORS           	-	V094	Treatment:Schizophrenia dx	BMI=40.3; Fasting Insulin (mU/mL) =15.8
SUBJECT_SAMPLE_FACTORS           	-	V097	Treatment:Schizophrenia dx	BMI=22.2; Fasting Insulin (mU/mL) =15.1
SUBJECT_SAMPLE_FACTORS           	-	V100	Treatment:Schizophrenia dx	BMI=35.1; Fasting Insulin (mU/mL) =39.2
SUBJECT_SAMPLE_FACTORS           	-	V110	Treatment:Schizophrenia dx	BMI=29.3; Fasting Insulin (mU/mL) =8.5
SUBJECT_SAMPLE_FACTORS           	-	V115	Treatment:Schizophrenia dx	BMI=32.5; Fasting Insulin (mU/mL) =29.0
SUBJECT_SAMPLE_FACTORS           	-	V116	Treatment:Schizophrenia dx	BMI=37.4; Fasting Insulin (mU/mL) =19.3
SUBJECT_SAMPLE_FACTORS           	-	V118	Treatment:Schizophrenia dx	BMI=45.7; Fasting Insulin (mU/mL) =25.6
SUBJECT_SAMPLE_FACTORS           	-	V123	Treatment:Schizophrenia dx	BMI=20.0; Fasting Insulin (mU/mL) =10.0
SUBJECT_SAMPLE_FACTORS           	-	V126	Treatment:Schizophrenia dx	BMI=24.5; Fasting Insulin (mU/mL) =14.0
SUBJECT_SAMPLE_FACTORS           	-	V129	Treatment:Schizophrenia dx	BMI=36.5; Fasting Insulin (mU/mL) =34.3
SUBJECT_SAMPLE_FACTORS           	-	V131	Treatment:Schizophrenia dx	BMI=34.5; Fasting Insulin (mU/mL) =17.6
SUBJECT_SAMPLE_FACTORS           	-	V133	Treatment:Schizophrenia dx	BMI=31.3; Fasting Insulin (mU/mL) =34.7
SUBJECT_SAMPLE_FACTORS           	-	V134	Treatment:Schizophrenia dx	BMI=35.0; Fasting Insulin (mU/mL) =18.0
SUBJECT_SAMPLE_FACTORS           	-	V135	Treatment:Schizophrenia dx	BMI=30.8; Fasting Insulin (mU/mL) =15.1
SUBJECT_SAMPLE_FACTORS           	-	V138	Treatment:Schizophrenia dx	BMI=36.7; Fasting Insulin (mU/mL) =26.4
SUBJECT_SAMPLE_FACTORS           	-	V139	Treatment:Schizophrenia dx	BMI=49.7; Fasting Insulin (mU/mL) =10.5
SUBJECT_SAMPLE_FACTORS           	-	V142	Treatment:Schizophrenia dx	BMI=28.7; Fasting Insulin (mU/mL) =9.6
SUBJECT_SAMPLE_FACTORS           	-	V144	Treatment:Schizophrenia dx	BMI=62.0; Fasting Insulin (mU/mL) =47.1
SUBJECT_SAMPLE_FACTORS           	-	V146	Treatment:Schizophrenia dx	BMI=25.7; Fasting Insulin (mU/mL) =18.7
SUBJECT_SAMPLE_FACTORS           	-	V147	Treatment:Schizophrenia dx	BMI=46.0; Fasting Insulin (mU/mL) =42.9
SUBJECT_SAMPLE_FACTORS           	-	V148	Treatment:Schizophrenia dx	BMI=28.2; Fasting Insulin (mU/mL) =10.6
SUBJECT_SAMPLE_FACTORS           	-	V149	Treatment:Schizophrenia dx	BMI=39.2; Fasting Insulin (mU/mL) =21.6
SUBJECT_SAMPLE_FACTORS           	-	V151	Treatment:Schizophrenia dx	BMI=26.3; Fasting Insulin (mU/mL) =19.9
SUBJECT_SAMPLE_FACTORS           	-	V154	Treatment:Schizophrenia dx	BMI=22.4; Fasting Insulin (mU/mL) =8.0
SUBJECT_SAMPLE_FACTORS           	-	V156	Treatment:Schizophrenia dx	BMI=39.0; Fasting Insulin (mU/mL) =86.4
SUBJECT_SAMPLE_FACTORS           	-	V158	Treatment:Schizophrenia dx	BMI=25.8; Fasting Insulin (mU/mL) =14.6
SUBJECT_SAMPLE_FACTORS           	-	V163	Treatment:Schizophrenia dx	BMI=22.8; Fasting Insulin (mU/mL) =9.4
SUBJECT_SAMPLE_FACTORS           	-	V165	Treatment:Schizophrenia dx	BMI=30.0; Fasting Insulin (mU/mL) =10.6
SUBJECT_SAMPLE_FACTORS           	-	V169	Treatment:Schizophrenia dx	BMI=30.9; Fasting Insulin (mU/mL) =13.3
SUBJECT_SAMPLE_FACTORS           	-	V172	Treatment:Schizophrenia dx	BMI=23.1; Fasting Insulin (mU/mL) =8.2
SUBJECT_SAMPLE_FACTORS           	-	V174	Treatment:Schizophrenia dx	BMI=24.2; Fasting Insulin (mU/mL) =18.6
SUBJECT_SAMPLE_FACTORS           	-	V179	Treatment:Schizophrenia dx	BMI=28.4; Fasting Insulin (mU/mL) =10.5
SUBJECT_SAMPLE_FACTORS           	-	V183	Treatment:Schizophrenia dx	BMI=41.0; Fasting Insulin (mU/mL) =38.8
SUBJECT_SAMPLE_FACTORS           	-	V187	Treatment:Schizophrenia dx	BMI=33.8; Fasting Insulin (mU/mL) =26.1
SUBJECT_SAMPLE_FACTORS           	-	V190	Treatment:Schizophrenia dx	BMI=32.0; Fasting Insulin (mU/mL) =35.4
SUBJECT_SAMPLE_FACTORS           	-	V191	Treatment:Schizophrenia dx	BMI=30.8; Fasting Insulin (mU/mL) =11.0
SUBJECT_SAMPLE_FACTORS           	-	V193	Treatment:Schizophrenia dx	BMI=36.5; Fasting Insulin (mU/mL) =14.8
SUBJECT_SAMPLE_FACTORS           	-	V194	Treatment:Schizophrenia dx	BMI=40.8; Fasting Insulin (mU/mL) =31.2
SUBJECT_SAMPLE_FACTORS           	-	V198	Treatment:Schizophrenia dx	BMI=23.8; Fasting Insulin (mU/mL) =7.0
SUBJECT_SAMPLE_FACTORS           	-	V202	Treatment:Schizophrenia dx	BMI=41.8; Fasting Insulin (mU/mL) =16.6
SUBJECT_SAMPLE_FACTORS           	-	V205	Treatment:Schizophrenia dx	BMI=45.7; Fasting Insulin (mU/mL) =58.2
SUBJECT_SAMPLE_FACTORS           	-	V209	Treatment:Schizophrenia dx	BMI=30.3; Fasting Insulin (mU/mL) =13.9
SUBJECT_SAMPLE_FACTORS           	-	V212	Treatment:Schizophrenia dx	BMI=31.2; Fasting Insulin (mU/mL) =16.5
SUBJECT_SAMPLE_FACTORS           	-	V214	Treatment:Schizophrenia dx	BMI=26.2; Fasting Insulin (mU/mL) =9.2
SUBJECT_SAMPLE_FACTORS           	-	V215	Treatment:Schizophrenia dx	BMI=25.9; Fasting Insulin (mU/mL) =9.3
SUBJECT_SAMPLE_FACTORS           	-	V216	Treatment:Schizophrenia dx	BMI=27.1; Fasting Insulin (mU/mL) =9.2
SUBJECT_SAMPLE_FACTORS           	-	V221	Treatment:Schizophrenia dx	BMI=33.5; Fasting Insulin (mU/mL) =23.4
SUBJECT_SAMPLE_FACTORS           	-	V223	Treatment:Schizophrenia dx	BMI=23.6; Fasting Insulin (mU/mL) =9.8
SUBJECT_SAMPLE_FACTORS           	-	V224	Treatment:Schizophrenia dx	BMI=29.8; Fasting Insulin (mU/mL) =15.8
SUBJECT_SAMPLE_FACTORS           	-	V225	Treatment:Schizophrenia dx	BMI=20.0; Fasting Insulin (mU/mL) =7.0
SUBJECT_SAMPLE_FACTORS           	-	V228	Treatment:Schizophrenia dx	BMI=20.9; Fasting Insulin (mU/mL) =10.0
SUBJECT_SAMPLE_FACTORS           	-	V232	Treatment:Schizophrenia dx	BMI=40.1; Fasting Insulin (mU/mL) =39.9
SUBJECT_SAMPLE_FACTORS           	-	V241	Treatment:Schizophrenia dx	BMI=34.9; Fasting Insulin (mU/mL) =35.9
SUBJECT_SAMPLE_FACTORS           	-	V249	Treatment:Schizophrenia dx	BMI=51.6; Fasting Insulin (mU/mL) =15.1
SUBJECT_SAMPLE_FACTORS           	-	V250	Treatment:Schizophrenia dx	BMI=27.6; Fasting Insulin (mU/mL) =16.1
SUBJECT_SAMPLE_FACTORS           	-	V252	Treatment:Schizophrenia dx	BMI=27.3; Fasting Insulin (mU/mL) =22.7
#COLLECTION
CO:COLLECTION_SUMMARY            	Fasting blood samples were collected via venipuncture into an additive-free vial
CO:COLLECTION_SUMMARY            	and allowed to coagulate at room temperature for 30 minutes. They were then
CO:COLLECTION_SUMMARY            	centrifuged for 15 minutes at 2500 rcf to obtain serum. Samples were frozen and
CO:COLLECTION_SUMMARY            	-80C, thawed once for sample processing related to the parent study, then kept
CO:COLLECTION_SUMMARY            	at -80C until processing for NMR and GC assays
CO:SAMPLE_TYPE                   	Blood (serum)
CO:STORAGE_CONDITIONS            	-80℃
CO:COLLECTION_VIALS              	Additive-free vacuatiner
#TREATMENT
TR:TREATMENT_SUMMARY             	N/A (observational study)
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	Serum samples were subjected to a 1:1 methanol:choloroform extraction, then
SP:SAMPLEPREP_SUMMARY            	dried with a speedvac. Prior to fatty acid analysis, the lipid fractions were
SP:SAMPLEPREP_SUMMARY            	resuspended and purified by TLC prior to GC analysis. This is described in more
SP:SAMPLEPREP_SUMMARY            	detail in the attached document, with sample prep summaries for the NMR
SP:SAMPLEPREP_SUMMARY            	component of this study included as well.
SP:SAMPLEPREP_PROTOCOL_ID        	EllingrodSamplePrepProtocol
SP:EXTRACTION_METHOD             	1:1 methanol:chloroform
SP:SAMPLE_RESUSPENSION           	hexane
SP:SAMPLE_SPIKING                	C17:0 methyl ester
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_TYPE           	GC
CH:INSTRUMENT_NAME               	Agilent 6890N
CH:COLUMN_NAME                   	Unspecified
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
#MS
MS:MS_COMMENTS                   	-
MS:INSTRUMENT_NAME               	-
MS:INSTRUMENT_TYPE               	-
MS:MS_TYPE                       	Other
MS:ION_MODE                      	UNSPECIFIED
#MS_METABOLITE_DATA
MS_METABOLITE_DATA:UNITS         	nmol
MS_METABOLITE_DATA_START
Samples	Q005	Q025	Q077	Q160	Q308	Q442	Q504	Q610	Q632	Q897	CCMB_04	CCMB_05	CCMB_15	CCMB_17	CCMB_19	P2721_22	P2721_23	P2721_27	P2721_28	P2721_40	V001	V003	V004	V008	V009	V011	V012	V013	V014	V015	V018	V019	V023	V029	V032	V033	V034	V035	V037	V041	V045	V046	V047	V048	V049	V052	V055	V056	V057	V063	V066	V068	V071	V079	V084	V087	V089	V092	V094	V097	V100	V110	V115	V116	V118	V123	V126	V129	V131	V133	V134	V135	V138	V139	V142	V144	V146	V147	V148	V149	V151	V154	V156	V158	V163	V165	V169	V172	V174	V179	V183	V187	V190	V191	V193	V194	V198	V202	V205	V209	V212	V214	V215	V216	V221	V223	V224	V225	V228	V232	V241	V249	V250	V252
Factors	Treatment:Obese control	Treatment:Obese control	Treatment:Obese control	Treatment:Obese control	Treatment:Obese control	Treatment:Obese control	Treatment:Obese control	Treatment:Obese control	Treatment:Obese control	Treatment:Obese control	Treatment:Non-obese control	Treatment:Non-obese control	Treatment:Non-obese control	Treatment:Non-obese control	Treatment:Non-obese control	Treatment:Non-obese control	Treatment:Non-obese control	Treatment:Non-obese control	Treatment:Non-obese control	Treatment:Non-obese control	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx	Treatment:Schizophrenia dx
14:00	17.27	7.08	20.34	13.42	15.43	7.67	12.29	34.16	7.03	13.49	5.43	6.16	6.41	9.54	8.96	2.65	3.22	2.15	5.53	2.26	29.93	31.59	13.33	40.69	26.47	11.74	15.47	24.12	14.08	9.51	11.94	14.87	12.32	15.42	29.65	27.36	25.32	27.05	10.58	10.87	5.75	19.48	34.22	20.63	9.1	102.62	29.85	37.75	21.95	11.9	3.39	9.37	36.05	8.17	22.27	41.25	21.21	22.82	18.57	15.86	17.21	11.38	10.8	11.83	13.09	7.19	11.93	8.23	35.01	20.82	31.17	9.54	21.71	4.2	5.38	17.48	13.19	5.92	30.77	6.99	7.06	5.58	24.3	2.73	8.42	6.58	6.17	7.47	18.67	4.65	29.79	47.06	11.57	83.94	7.95	7.14	13.52	18.79	18.63	5.3	27.28	21.48	11.05	13.47	32.85	13.51	8.14	1.93	3.4	19.48	14.26	9.35	8.32	12.65
14:1 (n-5)	2.8	1.91	3.7	2.11	0	1.44	2.54	3.42	0	0	1.54	1.84	0	0	0	1.73	0	0	0	1.11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4.27	0	0	0	9.89	0	0	0	1.27	0.55	1.05	3.58	0	0	0	0	0	1.33	0	1.3	0	0	0	1.94	1.65	0	0	0	0	0	0	0	0	0	0	0	0	0	1.36	1.65	1.3	0	0	0	0	1.64	1.9	2.5	1.67	3.42	4.88	0	9.29	0	1.33	2.6	3.28	2.6	0	3.5	0	2.39	0	0	0	0	0.57	1.55	0	0	0	0	0
16:00	567.93	490.93	733.26	762.9	756.84	355.45	565.76	902.41	417.3	735.05	380.85	442.13	337.86	515.95	521.08	359.7	436.2	231.4	376.11	197.34	808.28	827.33	568.46	987.12	754.41	690.46	664.58	736.18	590.38	602.65	587.52	643.2	529.27	333.91	861.62	854.44	606.11	715.55	439.82	580.59	386.05	466.82	885.55	701.27	285.04	1172.09	800.95	954.66	660.08	347.64	203.26	474.84	855.59	273.27	494	1051.88	703.13	753.79	775.4	337.4	599.75	455.06	400.05	662.28	583.93	381.69	474.13	435.14	894.97	589.39	978.53	369.18	918.08	528.82	418.87	820.86	752.47	456.68	1068.95	513.61	482.71	492.38	693.68	354.36	510.92	435.17	386.54	342.26	700.3	357.93	719.63	979.36	413.06	1528.78	344.42	337.95	805.68	629.56	601.28	369.11	976.97	790.18	891.98	841.32	962.9	694.61	781.91	229.74	500.72	1022.46	833.17	646.19	674.89	636.97
16:1 (n-7)	54.73	39.75	57.39	51.82	42.7	22.1	43.34	55.61	27.5	46.96	16.2	29.79	31.19	29.27	32.77	9.82	22.72	14.66	15.85	9.25	59.39	61.84	28.96	101.6	55.27	33.5	35.68	44.42	36.12	28.98	25.79	47.64	28.22	54.65	82.93	84.62	39.38	49.91	36.92	33.04	26.78	55.28	104.05	60.85	20.58	167.97	78.12	105.52	49.65	43.58	8.53	31.04	70.25	13.48	58.48	101.1	36.97	36.48	34.34	19.53	87.94	45.36	37.59	41.84	78.54	36.34	46.88	30.09	85.63	66.13	121.51	19.04	67.27	20.81	28.12	111.78	76.4	31.01	160.83	45.63	27.73	25.3	104.1	9.88	10.72	21.52	23.24	24.48	55.24	15.59	78.93	141.55	36.55	202.84	19.08	15.15	82.3	75.36	90.48	22.2	48.52	48.47	61	65.65	61.73	34.27	42.55	8.94	15.31	78.59	47.18	29.99	32.4	59.53
18:00	230.51	175.87	316.24	324.06	299.84	183.95	293.08	426.93	210.43	338.62	185.09	200.05	107.45	236.85	190.58	218.05	242.48	114.61	152.95	98.84	315.91	381.74	270.4	378.25	302.95	304.7	315.75	326.39	290.37	276.22	262.66	363.1	258.29	101.06	361.1	359.15	280.4	269.42	187.5	305.62	167.2	216.81	353.7	349.83	132.49	462.04	376.44	318.74	265.25	119.2	90.79	228.92	493.91	152.18	202.91	381.36	289.32	361.9	361.06	166.98	185.2	206.82	146.36	299.85	196.14	149.18	189.45	145.4	413.34	242.49	278.12	157.65	498.82	291.4	212.13	329.33	355.76	194.15	391.49	220.3	227.25	225.19	250.25	191.77	238.02	170.81	120.2	161.82	305.34	156.73	295.57	311.65	134.45	513.82	158.3	149.3	288.79	305.62	143.49	149.93	453.81	242.83	467.49	337.39	436.72	287.64	375.25	82.78	236.39	368.7	316.63	334	317.74	327.12
18:1(n-7)	35.66	46.65	50.16	64.53	67.04	24.04	35.2	65.42	36.64	59.43	28.54	32.48	22.16	36.17	39.36	20.25	29.98	13.19	24.02	16.48	67.2	37.88	35.76	64.73	46.01	51.01	44.42	39.86	30.61	42.5	37.3	45.12	33.28	29.73	53.61	53.53	31.31	53.67	35.75	38.25	33.45	32.99	54.31	51.11	23.5	66.28	60.81	63.06	39.53	28.17	12.14	25.49	32.95	14.97	48.41	69.2	45.95	41.58	40.39	15.61	44.8	39.62	26.04	40.26	35.6	25.61	44.11	38.03	78.83	39.88	82.5	25.41	54.65	44.63	40.5	100.04	72.95	39.4	97.59	44.73	24.02	29.95	56.08	24.65	35.8	29.25	26.18	24.26	30.71	28.01	54.89	52.18	30	100.79	28.71	20.17	38.91	41.02	55.88	29.21	62.84	52.48	78.31	63.46	55.42	42.9	48.5	20.65	36.89	52.32	63.19	49.32	32.87	37.38
18:1(n-9)	385.68	353.91	518.11	593.88	637.36	288.8	387.95	687.54	304.63	494.77	323.05	410.21	258.44	436.26	506.6	200.88	284.14	169.31	293.86	212.13	774.35	500.6	352.95	733.61	465.78	460.27	430.08	503.88	385.83	498.44	442.59	488.46	320.38	334.99	628.88	612.61	306.03	711.77	360.56	349.7	313.06	356.03	661.16	478.97	240.15	1007.6	547.86	711.54	478.04	378.7	153.34	314.54	539.74	175.55	374.87	980.8	565.55	474.44	423.58	231.74	603.49	301.39	365.54	421.37	359.86	375.73	419.15	357.5	695.27	485.85	1071.77	320.99	668.77	412.32	296.49	784.14	628.12	377.93	1105.18	500.73	341.25	370.36	600.99	297.41	428.6	335.73	329.14	315.91	563.1	307.55	650.62	653.07	334.3	1229.65	300.04	241.17	607.37	497.47	592.04	385.15	724.43	649.65	601.13	627.86	680.34	407.05	486.92	249.73	366.92	885.81	715.65	468.92	386.2	396.24
18:2 (n-6)	633.87	511.18	807.68	1102.21	1222.76	654.75	555.74	1142.91	504.22	967.69	666.22	452.02	295.03	600.95	896.1	485.88	735.08	311.37	689.74	389.18	856.26	658.96	584.53	672.98	721.29	752.17	687.05	772.67	579.74	611.12	823.16	863.37	445.04	205.16	671.64	711.74	625.2	880.55	460.99	693.93	334.22	522.49	573.31	660.9	401.9	1099.62	814.21	708.57	516.54	361.52	249.05	542.05	654.75	315.9	333.91	1055.46	829.51	616.49	574.58	394	362.66	393.22	440.23	668.18	473.47	526.55	536.24	456.72	1137	385.52	850.87	499.43	1117.14	677.66	545.49	799.56	898	490.93	1008.65	596.6	504.45	424.45	559.79	633.3	783.01	480.01	447.55	448.96	782.5	428.47	700.14	669.69	479.54	1544.73	505.05	407.56	793.64	674.93	424.68	555.59	1378.17	1005.94	1120.78	1079.03	1107.23	745.01	702.78	331.47	616.65	753.62	941.57	948.42	691.9	443.64
18:3 (n-3)	11.74	7.59	16.07	11.04	24.42	7.39	7.75	10.74	2.95	15.45	3.95	2.91	7.44	4.56	4.05	3.84	4.42	2.05	2.92	2.01	16.57	13.44	7.73	9.85	15.58	9.58	6.04	8.43	8	16.23	11.24	8.64	5.15	3.63	13.19	15.31	7	16.63	19.36	9.81	4.49	9.85	10.32	10.6	10.54	33.43	20.73	18.71	6.84	6.57	3.38	4.73	11.93	4.33	5.57	22.18	10.67	6.34	4.32	3.79	3.75	3.82	7.24	9.6	9.59	8.65	5.19	2.04	19.71	2.87	12.14	7.3	22.53	7.89	6.24	18.3	9.21	2.34	14.9	4.97	3.4	1.72	12.62	6.7	9.21	5.94	7.48	7.39	8.02	4.86	21.35	24.67	7.18	26.63	11.04	5.94	17.57	13.17	8.22	4.86	23.05	18.65	16.84	16.89	24.33	11.41	6.46	1.63	4.23	5.98	4.53	6.44	4.9	4.89
18:3 (n-6)	10.31	3.49	6.33	6.06	9.93	6.94	9.05	13.79	3.87	8.24	5.66	4.95	4.22	8.94	11.24	2.08	2.08	9.63	1.6	4.33	8.66	24.04	7.49	18.06	6.65	5.79	2.32	8.25	8.79	3.73	3.7	12.39	5.19	6.94	12.64	14.61	13.06	18.73	10.81	4.2	4.37	4.12	12.24	4.46	3.59	22.45	17.91	13.99	9.23	0.44	1.86	0.39	30.21	5.34	5.05	12.65	4.76	5.11	4.92	3.84	3.72	2.97	3.87	11.8	8.74	10.93	5.02	2.03	9.37	4.52	8.11	3.94	24.26	8.29	4.03	17.51	6.9	2.07	17.66	4.22	4.34	1.82	10.45	5.38	6.6	8.87	5.25	8.32	28.48	5.43	24.88	22.55	4.82	27.19	7.33	4.27	22.69	12.75	7.02	5.97	20.13	13.19	11.07	9.26	12.84	11.38	7.4	3.58	4.17	17	9.98	9.51	9.67	12.65
20:00	4.27	3.48	5.92	4.41	5.53	4.09	5.1	5.72	3.51	5.85	0.91	0	0	0	0	0	0	0	2.84	0	4.88	4.61	4.56	5.48	4.38	4.7	4.32	5.4	3.84	4.17	4.92	6.06	5.13	1.74	5.12	5.01	4.38	4.8	4.2	5.38	2.35	3.18	5.73	4.72	2.25	7.28	6.41	4.46	3.83	1.99	1.58	3.82	6.44	2.5	2.92	4.95	5.37	5.29	5.41	2.3	2.2	2.78	2.63	5.64	3.17	2.79	3.93	2.61	6	3.85	4.19	2.93	7.83	5.74	4.54	4.63	4.67	3.74	6.21	3.83	4.15	2.96	3.5	3.79	4.14	3.95	2.64	3.38	6.25	3.49	6.97	4.06	2.98	7.76	4.41	3.24	4.69	6.52	2.28	3.51	12.12	5.18	9.61	6.59	7.84	5.98	0	0	0	0	0	0	0	0
20:1 (n-9)	2.96	3.09	4.8	5.4	7.82	3.21	4.71	2.22	4.55	2.14	2.89	3.29	2.24	4.78	3.91	2.42	3.58	1.18	3.32	2.12	11.43	3.29	3.51	7.44	4.51	4.39	4.89	3.66	5.99	6.86	4.66	7.77	3.03	3.48	3.99	4.07	4.57	10.01	3.6	3.22	3.69	3.33	4.2	4.3	2.72	9.12	4.77	4.74	3.72	0.39	1.62	0.39	3.53	2.36	4.37	8.77	5.46	3.56	3.82	2.08	4.21	2.92	3.07	3.02	2.7	2.57	3.41	3.8	7.86	3.3	9.11	4.04	4.8	5.32	5.51	12.7	6.48	3.18	8.32	4.25	2.85	4.47	4.65	3.52	4.6	2.86	2.14	2.93	5.75	3.51	5.65	4.21	2.83	9.1	3.16	1.77	2.92	3.52	3.85	2.91	7.13	3.85	6.43	6.23	7.3	3.89	4.81	1.54	3.53	5.35	6.85	5.02	4.39	2.66
20:2 (n-6)	5.65	5.08	8.85	11.03	10.5	5.16	6.99	11.39	4.99	8.17	6.25	4.22	3.4	5.88	6.26	4.54	6.33	3.18	4.15	2.99	10.16	7.57	5.97	11.62	9.73	7.23	10	6.16	6.51	7.54	8.04	8.45	5.19	3.13	7.21	7.15	9.83	8.76	7.01	7.09	3.4	6.6	7.84	8.85	4.08	16.28	10.14	7.72	6.21	4.49	1.92	4.99	9.87	3.23	6.9	12.45	8.27	7.97	8.2	3.98	3.6	6.57	3.87	5.89	5.81	3.62	5.38	3.97	17.45	4.82	9.45	4.66	11.38	9.59	6.78	9.43	8.42	6.17	14.11	6.8	5.82	5.96	7.23	4.59	6.49	4.75	3.36	4.91	6.07	3.55	7.21	10.68	3.95	19.31	6.2	3.7	8.71	9.48	3.65	4.76	10.72	6.37	10.49	11.17	13.43	7.42	8.58	2.13	5.71	5.99	10.51	10.05	9.33	7.85
20:3 (n-6)	58.11	40.9	80.93	84.02	86.64	46.2	61.86	79.4	55	61.08	35.1	38.7	27.61	48.77	37.25	15.99	30.73	29.36	19.18	19.66	43.37	55.31	38.57	65.94	88.52	48.8	75.23	53.91	56.85	37.17	45.23	74.18	54.09	20.75	57.91	63.33	64.16	47.44	37.36	50.69	23.57	42.51	72.55	85.02	26.23	102.68	73.04	71.69	77.84	26.84	10.66	32.54	94.12	29.63	47.05	85.85	61.66	43.91	66.1	31.99	28.48	61.96	36.54	73.15	58.74	26.27	37.44	24.76	124.13	41.83	66.84	29.85	108.5	59.51	38.1	68.97	56.7	28.66	104.91	35.4	47.53	35.26	67.68	28.08	24.99	23.53	17.51	32.46	61.21	22.68	81.92	93.94	23.46	119.48	26.1	30.65	58.41	70.29	36.42	39.4	91.49	34.28	66	75.05	105.67	62.61	88.55	11.35	30.92	47.88	69.08	55.77	48.91	87.19
20:4 (n-6)	223.03	198.84	241.57	233.73	229.32	119.41	267.05	342.01	176.66	381.47	164.78	154.38	75.1	141.94	204.21	124.26	154	106.65	101.16	115	239.25	241.3	204.67	341.76	172.27	258.85	158.26	196.17	214.95	191.11	152.93	238.1	233.17	84.93	255.62	306.37	287.43	300.67	198.74	269.6	170.89	66.78	189.83	177.19	74.96	187.99	330.97	240.45	228.19	69.32	63.52	159.22	331.76	90.02	161.3	265.85	170.11	205	240.71	68.36	141.25	107.72	109.72	278.56	236.95	148.05	165.58	116.09	188.25	172.81	217.1	119.97	442.96	341.8	155.19	338.85	259.5	108.66	287.19	183.55	152.82	131.29	172.35	190.78	144.42	170.92	147.36	147.95	228.89	135.99	281.41	213.75	80.27	318.66	134.32	122.6	297.94	160.47	79.75	166.77	420.33	195.07	405.07	328.92	367.72	317.15	352.17	64.26	271.47	170.92	263.81	336.14	278.53	258.79
20:5 (n-3)	7.92	8.71	8.37	4.83	4.91	6.94	4.3	5.74	4.86	11.49	2.65	1.88	7.05	35.24	17.58	109.66	10.44	5.71	3.13	4.3	7.91	13.87	9.85	15.01	8.55	7.72	4.87	3.96	10.99	9.25	7.02	8.19	8.08	6.69	12.41	15.77	12.16	8.87	45.63	16.16	4.09	20.27	14.33	6.74	9.29	28.79	13.51	9.71	6.04	0.61	0.35	0.77	21.16	5.25	7.61	7.44	1.93	4.84	0.86	0.46	1.61	3.84	3.23	11.17	8.96	3.2	6.24	2.09	5.56	1.36	4.09	2.29	12.44	7.82	5.35	18.01	10.06	4.18	5.55	0.57	0.63	3.02	7.88	1.3	1.76	5.62	5.56	5.7	13.07	4.73	20.55	19.6	3.36	19.16	4.29	3.6	16.81	35.46	4.77	2.71	25.92	9.05	33.29	13.6	15.44	13.84	15.31	1.54	10.77	9.4	5.95	9.8	9.83	10.74
22:00	12.66	8.26	13.8	11.42	14.63	8.71	14.25	14.3	9.77	13.73	9.04	6.84	3.17	8.29	7.98	10.28	10.69	3.98	7.16	4.51	11.17	8.56	8.14	11.53	13.4	10.9	10.15	14.78	10.8	6.91	10.01	13.33	11	2.79	10.41	10.61	12.92	11.87	6.91	12.46	5.31	7.06	11.29	11.66	4.12	10.64	12.69	9.77	9.44	4.09	3.35	7.94	15.77	5.68	5.45	12.6	15.02	12.91	13.29	5.01	4.24	5.31	7.36	12.49	7.31	6.75	9.67	5.6	14.76	7.57	7.97	7.5	19.52	13.15	10.61	11.9	8.33	11.61	15.25	8.66	12.21	8.1	7.08	7.24	8.59	8.61	8.19	7.9	13.85	7.41	14.41	9.39	6.47	17.47	8.55	8.18	12.24	12.51	3.93	8.13	34.63	12.4	24.47	18.75	27.08	12.66	21.29	3.04	9.67	8.97	9.41	17.69	11.32	10.55
22:1 (n-9)	0	0	0.93	0	0	0.52	0.74	0	0	0	4.4	3.9	0	3.75	3.02	2.14	4.87	1.61	0	2.22	0	0.84	0	1.1	1.66	0.82	1.17	0	0	0	0	0	1.86	0	1.48	0	0.88	2.51	1.38	1.07	0	1.27	1.43	0.84	0	1.68	0.97	2.63	0	0.29	0.38	0.65	0.91	0	0.9	0	0.98	0	0.88	0.45	0.88	0	1.01	1.9	0.55	0.44	0	0	0	0	0	0	2.89	2.3	0	0	2.09	0	2.5	0.66	0.73	0.39	1.66	0	0	1.85	0.66	0.41	0.71	1.41	1.04	0.69	0	1.85	1.3	1.02	2.5	0.95	0	0	2.2	0	2.88	2.44	0	0	7.98	1	4.25	2.94	3.76	6.29	4.32	4.18
22:4 (n-6)	8.84	6.18	7.88	8.29	9.48	3.13	11.84	13.23	7.32	10.08	6.86	4.17	2.76	11.45	11.19	2.78	3.61	5.33	4	3.6	10.06	13.84	5.41	19.56	9.95	8.74	7.82	6.72	8	4.36	5.64	11.93	9.23	4.48	12.75	14.24	11.99	11.67	5.02	10.65	6.11	3.58	15.72	9.09	2.4	11.37	15.36	12.65	10.62	4.53	2.96	15.09	19.69	3.53	8.68	13.6	10.26	6.86	17.89	5.17	4.39	4.26	4.49	8.47	7.58	7.32	5.31	3.59	12.38	10.88	10.3	4.1	16.55	10.74	6.77	14.23	9.27	5.3	15.81	7.05	7.85	6.72	8.17	6	6.36	6.44	5.75	8.47	13.24	4.43	9.78	13.19	3.34	17	5.59	4.42	14.26	7.8	4.62	12.2	10.99	6.73	11.38	11.21	15.12	13.51	14.74	2.45	7.97	7.9	12.14	9.37	9.94	18.05
22:5 (n-3)	13.21	11.79	12.25	9.98	14.5	7.49	11.27	11.37	3.93	17.87	5.95	4.02	7.75	22.4	19.39	26.87	8.63	5.37	1.37	3.87	13.4	17.92	13.2	20.43	18.06	15.97	16.68	8.56	12.73	11.51	13.56	23.07	12.17	8.26	16.55	22.92	19.34	20.68	18.77	19.68	8.51	11.12	28.68	17.21	11.22	29.21	27.03	19.59	16.45	4.52	3.29	16.74	26.66	6.2	10.67	19.87	9.03	8.08	8.17	3.57	3.45	7.8	7.27	18.76	8.3	8.18	10.65	1.62	16.23	3.95	11.54	6.38	21.92	13.79	11.61	23.97	14.44	1.54	13.54	2.17	2.57	1.3	12.45	4.51	9.15	7.57	8.45	10.72	14.92	8.5	21.25	22.19	7.24	33.51	7.17	7.8	18.63	30.3	10.24	6.75	21.61	20.53	33.16	20.96	23.26	22.71	14.38	3.94	16.89	14.02	15.5	15.53	16.35	22.28
22:6 (n-3)	25.48	34.31	29.41	21.99	35.43	29.55	19.7	30.42	4.76	65.58	8.64	11.68	15.2	83.73	45.47	58.15	110.84	11.37	2.57	10.6	23.78	28.8	53.61	36.41	20.48	25.69	29.98	20.26	29.84	47.54	52.38	34.61	22.89	6.42	38.69	54.19	31.55	54.74	71.94	60.54	26.9	20.69	30.13	50.65	23.24	53.03	44.39	50.71	26.9	10.57	13.87	55.99	51.16	11.05	22.34	37.54	11.53	13.65	12.63	4.33	5.66	17.42	17.6	29.15	40.37	11.14	20.48	6	19.85	10.73	27.86	11.78	51.25	33.07	26.06	27.07	51.7	3.04	26.48	4.8	3.55	2.79	34.2	8.24	24.3	19.36	24.69	17.91	19.5	14.31	50.55	55.72	11.28	55.68	15.86	20.5	31.86	60.68	8.01	23.27	93.41	31.83	103.72	59.75	53.17	46.56	21.32	4.56	67.68	24.69	38.4	40.85	35.75	57.07
24:00:00	11.18	6.37	11.06	11.43	11.91	5.79	11.79	11.17	9.27	11.82	8.71	7.64	2.96	7.14	7.49	10.41	9.88	3.62	5.29	5.02	9.4	6.02	6.26	9.29	12.55	8.92	8.69	12.11	8.52	5.32	8.05	10.04	9.02	1.66	8.69	9.17	12.04	9.33	5.59	8.62	4.82	6.49	11.28	10.17	4.45	10.25	10.42	8.98	8.11	3.36	2.33	6.91	12.95	4.82	4.5	11.46	15.37	10.68	11.57	4.9	4.27	5.37	6.55	9.19	5.61	5.77	9.03	4.41	13.05	7.25	6.86	7.77	17.02	12.04	9.05	9.74	9.25	9.27	14.26	8.81	10.82	8.72	5.18	7.16	5.27	5.82	7.16	7.48	11.24	5.45	10.93	7.93	4.71	16.75	7.02	6.56	13.55	10.42	2.69	7.82	31.82	10.02	21.84	16.63	28.92	13.49	21.96	3.26	9.44	7.29	8.62	13.16	11.93	10.04
24:1 (n-9)	11.22	11.84	18.25	15.11	18.93	12.03	17.24	14.65	12.24	21.73	9.87	11.37	3.74	5.16	6.11	4.97	11.04	4.54	8.86	6.19	10.1	11.6	16.66	19.5	13.69	14.2	17.26	10.44	10.42	11.9	13.07	16.09	17.85	2.54	14.51	14.39	15.88	9.31	11.43	15.22	7.96	5.94	12.2	17.2	3.99	1.7	17.54	13.15	10.13	1.18	1.97	1.62	11.81	4.72	7.82	11.27	14.84	12.06	9.11	2.78	6.63	8	4.7	13.98	8.96	9.57	15.29	10.47	17.69	11.11	13.23	8.25	18.21	18.4	17.32	17.95	18.68	13.18	21.61	17.4	14.46	12.4	8.53	7.83	9.35	10.89	9.61	7.85	12.13	9.14	13.4	9.73	7.54	22.65	10.01	9.93	17.28	17.41	4.29	5.22	46.76	13.75	32.46	21.31	23.41	17.45	18.59	2.9	15.11	9.28	13.18	15.71	9.33	13.41
MS_METABOLITE_DATA_END
#METABOLITES
METABOLITES_START
metabolite_name	KEGG ID
14:00	C06424
14:1 (n-5)	C08322
16:00	C00249
16:1 (n-7)	C08362
18:00	C01530
18:1(n-7)	C08367
18:1(n-9)	C00712
18:2 (n-6)	C01595
18:3 (n-3)	C06427
18:3 (n-6)	C06426
20:00	C06425
20:1 (n-9)	C16526
20:2 (n-6)	C16525
20:3 (n-6)	C16522
20:4 (n-6)	C00219
20:5 (n-3)	C06428
22:00	C08281
22:1 (n-9)	C08316
22:4 (n-6)	C16527
22:5 (n-3)	C16513
22:6 (n-3)	C06429
24:00:00	C08320
24:1 (n-9)	C08323
METABOLITES_END
#END